Samsung and Biogen enter agreement to develop biosimilars

Yesterday, Samsung and Biogen announced that they have entered an agreement for the development, manufacturing, and marketing of biosimilars. Samsung Biologics was created in April of 2011 to specialize in biopharmaceutical products; with Biogen's experience in biologics manufacturing, both companies predict and expect rapid success. Samsung is to contribute $255 million for an 85 percent stake while Biogen is to contribute $45 million for a 15 percent stake in the joint venture. The completion of the transaction, which is to take place in Korea, will be subject to conditions including antitrust clearance by U.S and Korean regulators.

SOURCE: Biogen Press Release

0 Comments
Related Articles
Amylin and Lilly relationship breaks up
Two major pharmaceutical companies, Amylin Pharmaceuticals Inc (“Amylin”) and Eli Lilly and Company (“Lilly”), announced today their plans to terminate... Read More
GSK $3 billion lawsuit settlement forces pharma to more cautiously innovate
LONDON (Reuters) - GlaxoSmithKline Plc has agreed in principle to settle several long-standing disputes with the U.S. government over the... Read More